20
Participants
Start Date
April 21, 2021
Primary Completion Date
May 31, 2024
Study Completion Date
May 31, 2026
AV-MEL-1
AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
RECRUITING
Jericho Rabago, Irvine
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
Lead Sponsor
Aivita Biomedical, Inc.
INDUSTRY